Your browser doesn't support javascript.
loading
A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.
Mayer, Daniel P; Nelson, Mariah E; Andriyanova, Daria; Filler, Renata B; Ökten, Arya; Antao, Olivia Q; Chen, Jennifer S; Scumpia, Philip O; Weaver, Westbrook M; Wilen, Craig B; Deshayes, Stephanie; Weinstein, Jason S.
Afiliación
  • Mayer DP; Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ 07103, United States of America.
  • Nelson ME; Tempo Therapeutics, 3030 Bunker Hill st., suite 104, San Diego, CA 92109, United States of America.
  • Andriyanova D; Tempo Therapeutics, 3030 Bunker Hill st., suite 104, San Diego, CA 92109, United States of America.
  • Filler RB; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06510, United States of America.
  • Ökten A; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06510, United States of America; Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06510, United States of America.
  • Antao OQ; Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ 07103, United States of America.
  • Chen JS; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06510, United States of America; Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06510, United States of America.
  • Scumpia PO; Department of Medicine, Division of Dermatology, University of California Los Angeles, Los Angeles, California, United States of America; Department of Dermatology, West Los Angeles Veteran Affairs Medical Center, Los Angeles, California, United States of America.
  • Weaver WM; Tempo Therapeutics, 3030 Bunker Hill st., suite 104, San Diego, CA 92109, United States of America.
  • Wilen CB; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06510, United States of America; Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06510, United States of America.
  • Deshayes S; Tempo Therapeutics, 3030 Bunker Hill st., suite 104, San Diego, CA 92109, United States of America.
  • Weinstein JS; Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ 07103, United States of America. Electronic address: jason.weinstein@rutgers.edu.
J Control Release ; 370: 570-582, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38734312
ABSTRACT
Current antigen delivery platforms, such as alum and nanoparticles, are not readily tunable, thus may not generate optimal adaptive immune responses. We created an antigen delivery platform by loading lyophilized Microporous Annealed Particle (MAP) with aqueous solution containing target antigens. Upon administration of antigen loaded MAP (VaxMAP), the biomaterial reconstitution forms an instant antigen-loaded porous scaffold area with a sustained release profile to maximize humoral immunity. VaxMAP induced CD4+ T follicular helper (Tfh) cells and germinal center (GC) B cell responses in the lymph nodes similar to Alum. VaxMAP loaded with SARS-CoV-2 spike protein improved the magnitude, neutralization, and duration of anti-receptor binding domain antibodies compared to Alum vaccinated mice. A single injection of Influenza specific HA1-loaded-VaxMAP enhanced neutralizing antibodies and elicited greater protection against influenza virus challenge than HA1-loaded-Alum. Thus, VaxMAP is a platform that can be used to promote adaptive immune cell responses to generate more robust neutralizing antibodies, and better protection upon pathogen challenge.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunidad Humoral / Glicoproteína de la Espiga del Coronavirus / Vacunas contra la COVID-19 / COVID-19 Límite: Animals Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunidad Humoral / Glicoproteína de la Espiga del Coronavirus / Vacunas contra la COVID-19 / COVID-19 Límite: Animals Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos